verapamil [Ligand Id: 2406] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL6966 (Calan, Covera-HS, CP-16,533-1, CP-16533-1, CP-165331, D-365, Iproveratril, Isoptin, NSC-272306NA, Tarka, Verapamil, Verapamil slow release, Verelan) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| α1A-adrenoceptor/Alpha-1a adrenergic receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL319] [GtoPdb: 22] [UniProtKB: P43140] | ||||||||
| ChEMBL | DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) | B | 6.07 | pKi | 847 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) | B | 5.68 | pIC50 | 2092 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| α1B-adrenoceptor/Alpha-1b adrenergic receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL315] [GtoPdb: 23] [UniProtKB: P15823] | ||||||||
| ChEMBL | DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) | B | 6.03 | pKi | 940 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) | B | 5.77 | pIC50 | 1698 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| α2A-adrenoceptor/Alpha-2a adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1867] [GtoPdb: 25] [UniProtKB: P08913] | ||||||||
| ChEMBL | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | B | 6.66 | pKi | 217 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | B | 6.24 | pIC50 | 579 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| ABCG2/ATP-binding cassette sub-family G member 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5393] [GtoPdb: 792] [UniProtKB: Q9UNQ0] | ||||||||
| ChEMBL | TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells | F | 4.3 | pIC50 | >50000 | nM | IC50 | Mol Pharmacol (2004) 65: 1485-1495 [PMID:15155841] |
| ChEMBL | Reversal of BCRP-mediated multidrug resistance in human KBV cells assessed as mitoxantrone IC50 at 10 uM after 72 hrs in presence of mitoxantrone by MTT assay (Rvb = 1186.50 +/- 29.24 nM) | B | 5.92 | pIC50 | 1193.38 | nM | IC50 | Eur J Med Chem (2021) 216: 113317-113317 [PMID:33706147] |
| ChEMBL | Modulation of BCRP1 mediated drug efflux in mitoxantrone-resistant human MES-SA cells assessed as accumulation of hoechst 33342 incubated for 15 mins prior to rhodamine-123 addition measured after 90 mins by fluorescence analysis | B | 4.43 | pEC50 | 37300 | nM | EC50 | Bioorg Med Chem (2014) 22: 5860-5870 [PMID:25311564] |
| ChEMBL | Inhibition of BCRP (unknown origin) expressed in MDCK cells assessed as increase in Hoechst 33342 accumulation incubated for 30 mins by Hoechst 33342 dye based fluorescence assay | B | 6.05 | pEC50 | 900 | nM | EC50 | Eur J Med Chem (2019) 182: 111655-111655 [PMID:31494468] |
| ABCB11/Bile salt export pump in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6020] [GtoPdb: 778] [UniProtKB: O95342] | ||||||||
| ChEMBL | TP_TRANSPORTER: increase in bodipy intracellular accumulation (Bodipy: 0.2 uM) in SK-E2 cells (expressing BSEP) | F | 4.1 | pIC50 | 79100 | nM | IC50 | Pharm Res (2003) 20: 537-544 [PMID:12739759] |
| ABCC2/Canalicular multispecific organic anion transporter 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5748] [GtoPdb: 780] [UniProtKB: Q92887] | ||||||||
| ChEMBL | Reversal of MRP2-mediated multidrug resistance in human KBV cells assessed as cisplatin IC50 at 10 uM after 72 hrs in presence of cisplatin by MTT assay (Rvb = 4902.89 +/- 130.33 nM) | B | 5.3 | pIC50 | >5000 | nM | IC50 | Eur J Med Chem (2021) 216: 113317-113317 [PMID:33706147] |
| Chloroquine resistance transporter in Plasmodium falciparum (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795182] [UniProtKB: Q9N623] | ||||||||
| ChEMBL | Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-chloroquine transportation after 1 to 2 hrs | B | 4.48 | pIC50 | 33000 | nM | IC50 | ACS Med Chem Lett (2014) 5: 576-581 [PMID:24900883] |
| ChEMBL | Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocyte assessed as inhibition of [3H]chloroquine uptake measured from 1 to 2 hrs | B | 4.52 | pIC50 | 30000 | nM | IC50 | J Med Chem (2012) 55: 6948-6967 [PMID:22783984] |
| ChEMBL | Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes assessed as reduction in [3H]-chloroquine uptake after 1.5 to 2 hrs | B | 4.52 | pIC50 | 30000 | nM | IC50 | J Med Chem (2012) 55: 10387-10404 [PMID:23145816] |
| D3 receptor/Dopamine D3 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL234] [GtoPdb: 216] [UniProtKB: P35462] | ||||||||
| ChEMBL | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | B | 7.2 | pKi | 63 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | B | 6.73 | pIC50 | 186 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| Kv11.1/HERG in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809] | ||||||||
| ChEMBL | Inhibitory concentration against IKr potassium channel | B | 5.51 | pIC50 | 3100 | nM | IC50 | Bioorg Med Chem Lett (2004) 14: 4771-4777 [PMID:15324906] |
| ChEMBL | Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by patch clamp method | B | 6.28 | pIC50 | 530 | nM | IC50 | Bioorg Med Chem (2017) 25: 5341-5354 [PMID:28797771] |
| ChEMBL | Inhibition of human ERG | B | 6.4 | pIC50 | 400 | nM | IC50 | J Med Chem (2020) 63: 5865-5878 [PMID:32390424] |
| ChEMBL | Inhibition of human ERG stably expressed in CHO-K1 cells at -90 mV holding potential by automated Q-patch clamp method | B | 6.7 | pIC50 | 200 | nM | IC50 | ACS Med Chem Lett (2021) 12: 1333-1341 [PMID:34413963] |
| ChEMBL | Inhibition of human ERG in MCF7 cells | B | 6.84 | pIC50 | 144.54 | nM | IC50 | Eur J Med Chem (2009) 44: 1926-1932 [PMID:19110341] |
| ChEMBL | Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state | F | 6.84 | pIC50 | 144.54 | nM | IC50 | Bioorg Med Chem Lett (2005) 15: 1737-1741 [PMID:15745831] |
| ChEMBL | Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1 | B | 6.84 | pIC50 | 143 | nM | IC50 | Bioorg Med Chem Lett (2003) 13: 1829-1835 [PMID:12729675] |
| ChEMBL | K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1 | F | 6.84 | pIC50 | 143 | nM | IC50 | J Med Chem (2002) 45: 3844-3853 [PMID:12190308] |
| ChEMBL | Inhibition of hERG K channel | F | 6.84 | pIC50 | 143 | nM | IC50 | Cardiovasc Res (2011) 91: 53-61 [PMID:21300721] |
| ChEMBL | Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique | B | 6.85 | pIC50 | 141.25 | nM | IC50 | Bioorg Med Chem (2008) 16: 6252-6260 [PMID:18448342] |
| ChEMBL | Inhibitory concentration against potassium channel HERG | B | 6.85 | pIC50 | 141.25 | nM | IC50 | Bioorg Med Chem Lett (2005) 15: 2886-2890 [PMID:15911273] |
| ChEMBL | Inhibition of human Potassium channel HERG expressed in mammalian cells | B | 6.85 | pIC50 | 141.25 | nM | IC50 | Bioorg Med Chem Lett (2003) 13: 2773-2775 [PMID:12873512] |
| ChEMBL | Inhibition of human ERG | B | 6.85 | pIC50 | 141.25 | nM | IC50 | Eur J Med Chem (2011) 46: 618-630 [PMID:21185626] |
| ChEMBL | Inhibition of human ERG | B | 8 | pIC50 | 10 | nM | IC50 | J Med Chem (2013) 56: 8955-8971 [PMID:23919353] |
| H2 receptor/Histamine H2 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1941] [GtoPdb: 263] [UniProtKB: P25021] | ||||||||
| ChEMBL | DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) | B | 5.59 | pKi | 2547 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) | B | 5.59 | pIC50 | 2590 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| ABCC1/Multidrug resistance-associated protein 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3004] [GtoPdb: 779] [UniProtKB: P33527] | ||||||||
| ChEMBL | Inhibition of MRP1 in human 2008/MRP1 cells by dixon plot analysis | B | 4.87 | pKi | 13400 | nM | Ki | J Med Chem (2009) 52: 5311-5322 [PMID:19725578] |
| ChEMBL | Inhibition of MRP1 in human 2008/MRP1 cells by Lineweaver-Burke plot analysis | B | 4.88 | pKi | 13200 | nM | Ki | J Med Chem (2009) 52: 5311-5322 [PMID:19725578] |
| ChEMBL | Inhibition of human MRP1 in human 2008 cells | B | 5.02 | pIC50 | 9660 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 4761-4763 [PMID:18707884] |
| ChEMBL | Inhibition of MRP1 expressed in MDCK cells assessed as calcein AM accumulation after 30 mins by fluorescence assay | B | 5.17 | pIC50 | 6800 | nM | IC50 | J Med Chem (2012) 55: 424-436 [PMID:22112208] |
| ChEMBL | Inhibition of MRP1 (unknown origin) expressed in MDCK cells assessed as reduction in calcein-AM efflux preincubated for 30 mins followed by calcein-AM addition measured after 30 mins by spectrofluorimetric method | B | 5.35 | pIC50 | 4500 | nM | IC50 | Eur J Med Chem (2019) 161: 433-444 [PMID:30384046] |
| ChEMBL | Inhibition of MRP1 (unknown origin) expressed in MDCK cells after 30 mins by Calcein-AM assay | B | 5.46 | pIC50 | 3500 | nM | IC50 | J Med Chem (2014) 57: 6403-6418 [PMID:25093931] |
| ChEMBL | Modulation of MRP1 mediated drug efflux in doxorubicin-resistant human H69 cells assessed as accumulation of calcein AM incubated for 15 mins prior to calcein AM addition measured after 30 mins by fluorescence analysis | B | 4.56 | pEC50 | 27800 | nM | EC50 | Bioorg Med Chem (2014) 22: 5860-5870 [PMID:25311564] |
| ChEMBL | Inhibition of MRP1 (unknown origin) expressed in MDCK cells assessed as increase in calcein-AM accumulation incubated for 30 mins by calcein-AM dye based fluorescence assay | B | 5.17 | pEC50 | 6800 | nM | EC50 | Eur J Med Chem (2019) 182: 111655-111655 [PMID:31494468] |
| ChEMBL | Inhibition of MRP1 (unknown origin) in MDCK-MDR1 assessed as inhibtion of calcein-AM transport incubated for 30 mins by fluorescence assay | B | 5.17 | pEC50 | 6800 | nM | EC50 | Eur J Med Chem (2019) 172: 71-94 [PMID:30947123] |
| ChEMBL | Inhibition of MRP1 in human 2008/MRP1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring reduction in cell survival after 5 days by MTS assay | B | 5.72 | pEC50 | 1925 | nM | EC50 | J Med Chem (2018) 61: 9931-9951 [PMID:30351934] |
| Muscarinic acetylcholine receptor M2 in Pig (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4781] [UniProtKB: P06199] | ||||||||
| ChEMBL | Ability to dissociate radioligand [3H]NMS from muscarinic acetylcholine receptor M2 of porcine heart | B | 4.51 | pEC50 | 30974.19 | nM | EC50 | J Med Chem (2003) 46: 1390-1407 [PMID:12672239] |
| Translocator protein/Peripheral-type benzodiazepine receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4552] [GtoPdb: 2879] [UniProtKB: P16257] | ||||||||
| ChEMBL | Ability to inhibit [3H]-PK 11195 binding to peripheral-type benzodiazepine receptor(PBR) in rat cerebral cortex homogenate. | B | 8.85 | pIC50 | 1.4 | nM | IC50 | J Med Chem (1996) 39: 2922-2938 [PMID:8709127] |
| ABCB1/P-glycoprotein 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4302] [GtoPdb: 768] [UniProtKB: P08183] | ||||||||
| ChEMBL | TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells | F | 4.82 | pKi | 15100 | nM | Ki | Pharm Res (2002) 19: 765-772 [PMID:12134945] |
| ChEMBL | TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells | F | 5.52 | pKi | 3000 | nM | Ki | Pharm Res (2001) 18: 171-176 [PMID:11405287] |
| ChEMBL | Concentration giving half of the maximal ATPase activity calculated for the high-affinity binding site of the CHO P-Glycoprotein (P-gp) in two-affinity model | B | 5.6 | pKi | 2500 | nM | Ki | J Med Chem (2002) 45: 5671-5686 [PMID:12477351] |
| ChEMBL | Competitive inhibition of P-gp overexpressed in human MDA435/LCC6MDR cells assessed as accumulation of doxorubicin by Dixon plot analysis | B | 5.76 | pKi | 1750 | nM | Ki | J Med Chem (2012) 55: 1999-2014 [PMID:22320402] |
| ChEMBL | Competitive inhibition of P-gp overexpressed in human MDA435/LCC6MDR cells assessed as accumulation of doxorubicin by Lineweaver-Burk plot analysis | B | 5.76 | pKi | 1750 | nM | Ki | J Med Chem (2012) 55: 1999-2014 [PMID:22320402] |
| ChEMBL | TP_TRANSPORTER: transepithelial transport of digoxin (basal to apical) in Caco-2 cells | F | 6.06 | pKi | 880 | nM | Ki | Pharm Res (2003) 20: 161-168 [PMID:12636153] |
| ChEMBL | High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model | B | 6.52 | pKi | 300 | nM | Ki | J Med Chem (2002) 45: 5671-5686 [PMID:12477351] |
| ChEMBL | Inhibition of P-gp in human KB-V1/Vbl cells assessed as calcein-AM accumulation preincubated for 15 mins followed by calcein-AM addition measured after 15 mins by fluorescence assay | B | 4.18 | pIC50 | 65600 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 5168-5171 [PMID:27727127] |
| ChEMBL | Evaluated for cytotoxicity using P388/VMDRC.04 cells (a subline of P388 murine leukemia cells expressing human recombinant human P-glycoprotein) in the absence of 10 nM vincristine | F | 4.28 | pIC50 | 53000 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 1541-1546 [PMID:10386932] |
| ChEMBL | TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells | F | 4.38 | pIC50 | 42000 | nM | IC50 | Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514] |
| ChEMBL | TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells | F | 4.42 | pIC50 | 38200 | nM | IC50 | Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514] |
| ChEMBL | Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured immediately by MTT assay (Rvb = 51.34 +/- 5.1 uM) | B | 4.5 | pIC50 | 31280 | nM | IC50 | Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831] |
| ChEMBL | TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells | F | 4.54 | pIC50 | 28900 | nM | IC50 | Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514] |
| ChEMBL | Inhibition of ABCB1 (unknown origin) expressed in HEK293T cells assessed as reduction in paclitaxel IC50 at 2 uM pre-incubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay | B | 4.69 | pIC50 | 20200 | nM | IC50 | J Med Chem (2021) 64: 14895-14911 [PMID:34546748] |
| ChEMBL | TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells | F | 4.72 | pIC50 | 18900 | nM | IC50 | J Pharmacol Exp Ther (2003) 305: 197-204 [PMID:12649369] |
| ChEMBL | Inhibition of human recombinant P-glycoprotein after 40 mins by Pgp-Glo assay | B | 4.74 | pIC50 | 18000 | nM | IC50 | J Med Chem (2012) 55: 8152-8163 [PMID:22916727] |
| ChEMBL | Reversal of P-gp mediated multidrug resistance in human MCF7/ADM cells assessed as doxorubicin IC50 at 5 uM measured within 48 hrs by MTT assay (Rvb = 151.7 +/- 5 uM) | B | 4.75 | pIC50 | 17800 | nM | IC50 | Eur J Med Chem (2019) 183: 111726-111726 [PMID:31585275] |
| ChEMBL | Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 at 5 uM measured after 48 hrs by MTT assay (Rvb = 43.75 to 96.91 uM) | B | 4.76 | pIC50 | 17550 | nM | IC50 | Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831] |
| ChEMBL | Inhibition of human MDR1 expressed in MDCK2 cells assessed as enhancement of Calcein-AM uptake treated 30 mins before Calcein-AM challenge measured after 20 mins | B | 4.85 | pIC50 | 14000 | nM | IC50 | J Med Chem (2009) 52: 3328-3341 [PMID:19402665] |
| ChEMBL | Inhibition of human P-glycoprotein 1 ATPase activity assessed as remaining ATP level by luminescence analysis | B | 4.92 | pIC50 | 12000 | nM | IC50 | Medchemcomm (2013) 4: 278-288 |
| ChEMBL | Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK-8 assay | B | 4.92 | pIC50 | 11900 | nM | IC50 | Eur J Med Chem (2021) 216: 113336-113336 [PMID:33725657] |
| ChEMBL | Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 measured after 48 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM) | B | 4.97 | pIC50 | 10730 | nM | IC50 | Bioorg Med Chem (2017) 25: 4194-4202 [PMID:28645831] |
| ChEMBL | Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of irinotecan-induced cytotoxicity by measuring irinotecan IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 49.2 +/- 0.46 nM) | B | 4.98 | pIC50 | 10370 | nM | IC50 | Eur J Med Chem (2019) 182: 111668-111668 [PMID:31505451] |
| ChEMBL | Reversal of P-gp-mediated multidrug resistance in human MCF7/Dox cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 12.5 uM after 48 hrs by MTT assay (Rvb = 51.19 +/- 0.95 microM) | B | 5 | pIC50 | 10100 | nM | IC50 | Eur J Med Chem (2019) 180: 350-366 [PMID:31325783] |
| ChEMBL | Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry | B | 5.01 | pIC50 | 9800 | nM | IC50 | Bioorg Med Chem (2011) 19: 2090-2102 [PMID:21354800] |
| ChEMBL | TP_TRANSPORTER: transepithelial transport of fexofenadine in Caco-2 cells | F | 5.07 | pIC50 | 8440 | nM | IC50 | Pharm Res (2004) 21: 1398-1404 [PMID:15359574] |
| ChEMBL | Inhibition of P-glycoprotein by Hoechst assay | B | 5.18 | pIC50 | 6606.93 | nM | IC50 | Bioorg Med Chem (2007) 15: 7470-7479 [PMID:17890094] |
| ChEMBL | Inhibition of human Pgp in A2780 cells after 30 mins by Hoechst 33342 assay | B | 5.18 | pIC50 | 6606.93 | nM | IC50 | Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034] |
| ChEMBL | TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells | F | 5.19 | pIC50 | 6500 | nM | IC50 | Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514] |
| ChEMBL | Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM by measuring adriamycin IC50 after 48 hrs by MTT assay | B | 5.19 | pIC50 | 6470 | nM | IC50 | J Med Chem (2021) 64: 6179-6197 [PMID:33938746] |
| ChEMBL | Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay | F | 5.2 | pIC50 | 6300 | nM | IC50 | J Med Chem (2003) 46: 1716-1725 [PMID:12699389] |
| ChEMBL | TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells | F | 5.2 | pIC50 | 6300 | nM | IC50 | J Med Chem (2003) 46: 1716-1725 [PMID:12699389] |
| ChEMBL | Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 398.34 +/- 0.58 uM) | B | 5.21 | pIC50 | 6150 | nM | IC50 | Eur J Med Chem (2019) 161: 364-377 [PMID:30384042] |
| ChEMBL | Inhibition of Pgp by daunorubicin accumulation assay | B | 5.24 | pIC50 | 5800 | nM | IC50 | Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034] |
| ChEMBL | Inhibition of Pgp by daunorubicin accumulation assay | B | 5.24 | pIC50 | 5754.4 | nM | IC50 | Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034] |
| ChEMBL | Inhibition of P-gp in human A2780 cells | B | 5.27 | pIC50 | 5420 | nM | IC50 | Bioorg Med Chem Lett (2008) 18: 4761-4763 [PMID:18707884] |
| ChEMBL | Inhibition of P-glycoprotein-mediated multidrug resistance in adriamycin-resistant human A2780/ADR cells by calcein AM assay | B | 5.28 | pIC50 | 5200 | nM | IC50 | Bioorg Med Chem (2009) 17: 2524-2535 [PMID:19250834] |
| ChEMBL | TP_TRANSPORTER: drug resistance (paclitaxel) in MES-SA/DX5 cells | F | 5.32 | pIC50 | 4780 | nM | IC50 | Anticancer Drugs (2003) 14: 175-181 [PMID:12569305] |
| ChEMBL | TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells | F | 5.33 | pIC50 | 4700 | nM | IC50 | Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514] |
| ChEMBL | Inhibition of P-gp in doxorubicin-resistant human MCF7/ADR cells assessed as reversal of doxorubicin resistance by measuring doxorubicin IC50 incubated for 48 hrs by MTT assay (Rvb = doxorubicin alone = 64.8 +/- 2.1 uM) | B | 5.33 | pIC50 | 4700 | nM | IC50 | J Nat Prod (2019) 82: 724-734 [PMID:30860373] |
| ChEMBL | Reversal of P-gp mediated multidrug resistance in human HepG2/DOX cells assessed as doxorubicin IC50 at 5 uM measured within 48 hrs by MTT assay (Rvb = 69.3 +/- 3.9 uM) | B | 5.33 | pIC50 | 4700 | nM | IC50 | Eur J Med Chem (2019) 183: 111726-111726 [PMID:31585275] |
| ChEMBL | Inhibition of P-glycoprotein expressed in A2780/ADR cells by calcein AM assay | B | 5.34 | pIC50 | 4570.88 | nM | IC50 | Bioorg Med Chem (2007) 15: 7470-7479 [PMID:17890094] |
| ChEMBL | Inhibition of P-gp in human adriamycin-resistant A2780 cells by Hoechst 33342 assay | B | 5.34 | pIC50 | 4570.88 | nM | IC50 | Bioorg Med Chem (2008) 16: 8224-8236 [PMID:18678495] |
| ChEMBL | Inhibition of human Pgp in A2780 cells after 30 mins by calcein AM assay | B | 5.34 | pIC50 | 4570.88 | nM | IC50 | Bioorg Med Chem (2008) 16: 2448-2462 [PMID:18083034] |
| ChEMBL | TP_TRANSPORTER: inhibition of Daunorubicin efflux (Daunorubicin: ? uM) in G185 cells | F | 5.38 | pIC50 | 4200 | nM | IC50 | Drug Metab Dispos (2001) 29: 1080-1083 [PMID:11454724] |
| ChEMBL | TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells | F | 5.38 | pIC50 | 4200 | nM | IC50 | Biochem Biophys Res Commun (2001) 289: 580-585 [PMID:11716514] |
| ChEMBL | Reversal of P-gp mediated multidrug resistance in human MCF7/ADM cells assessed as doxorubicin IC50 at 10 uM measured within 48 hrs by MTT assay (Rvb = 151.7 +/- 5 uM) | B | 5.43 | pIC50 | 3700 | nM | IC50 | Eur J Med Chem (2019) 183: 111726-111726 [PMID:31585275] |
| ChEMBL | Multidrug-resistant reversal activity using P388/VMDRC.04 cells (a subline of P388 murine leukemia cells expressing human recombinant human P-glycoprotein) in the presence of 10 nM vincristine | F | 5.51 | pIC50 | 3100 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 1541-1546 [PMID:10386932] |
| ChEMBL | Reversal of Pgp-mediated DOX resistance in human SW620/AD300 cells assessed as potentiation of DOX-induced cytotoxicity by measuring DOX IC50 at 1 uM incubated for 48 hrs by SRB assay (Rvb = 33.39 +/- 7.08 uM) | B | 5.53 | pIC50 | 2980 | nM | IC50 | J Med Chem (2020) 63: 5458-5476 [PMID:32329342] |
| ChEMBL | TP_TRANSPORTER: drug resistance (paclitaxel) in HCT15/CL02 cells | F | 5.66 | pIC50 | 2210 | nM | IC50 | Anticancer Drugs (2003) 14: 175-181 [PMID:12569305] |
| ChEMBL | Concentration required for 50% inhibition (racemic) at binding site of human P-Glycoprotein (P-gp) in one-affinity model | B | 5.68 | pIC50 | 2110 | nM | IC50 | J Med Chem (2002) 45: 5671-5686 [PMID:12477351] |
| ChEMBL | TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells | F | 5.68 | pIC50 | 2100 | nM | IC50 | Drug Metab Dispos (2000) 28: 655-660 [PMID:10820137] |
| ChEMBL | Inhibition of P-glycoprotein 1 in human HeLa cells assessed as intracellular accumulation of Hoechst 33342 dye after 30 mins by fluorescence microscopic analysis | B | 5.77 | pIC50 | 1700 | nM | IC50 | Medchemcomm (2013) 4: 278-288 |
| ChEMBL | Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluorometric analysis | B | 5.8 | pIC50 | 1600 | nM | IC50 | Bioorg Med Chem (2013) 21: 456-465 [PMID:23245571] |
| ChEMBL | Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model | B | 5.83 | pIC50 | 1480 | nM | IC50 | J Med Chem (2002) 45: 5671-5686 [PMID:12477351] |
| ChEMBL | Reversal of P-gp mediated multidrug resistance in human HepG2/DOX cells assessed as doxorubicin IC50 at 10 uM measured within 48 hrs by MTT assay (Rvb = 69.3 +/- 3.9 uM) | B | 5.89 | pIC50 | 1300 | nM | IC50 | Eur J Med Chem (2019) 183: 111726-111726 [PMID:31585275] |
| ChEMBL | Inhibition of MDR1 (unknown origin) expressed in MDCK cells assessed as reduction in calcein-AM efflux preincubated for 30 mins followed by calcein-AM addition measured after 30 mins by spectrofluorimetric method | B | 5.89 | pIC50 | 1300 | nM | IC50 | Eur J Med Chem (2019) 161: 433-444 [PMID:30384046] |
| ChEMBL | Inhibition of P-gp in human 12D7-MDR cells using calcein-AM as substrate | B | 5.92 | pIC50 | 1200 | nM | IC50 | J Med Chem (2020) 63: 2131-2138 [PMID:31505928] |
| ChEMBL | Reversal of P-gp mediated multidrug resistance in human SW620/AD300 cells assessed as potentiation of doxorubicin-induced antiproliferative activity by measuring doxorubicin IC50 at 2.5 uM after 48 hrs by MTT assay (Rvb = 4.9 microM) | B | 6.09 | pIC50 | 810 | nM | IC50 | J Nat Prod (2020) 83: 497-504 [PMID:31975579] |
| ChEMBL | Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00 +/- 0.24 uM) | B | 6.13 | pIC50 | 740 | nM | IC50 | Eur J Med Chem (2014) 87: 398-412 [PMID:25282263] |
| ChEMBL | Inhibition of ABCB1 in human KB-VIN cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 4736 +/- 59 nM) | B | 6.15 | pIC50 | 708 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of P-glycoprotein overexpressed in human SW620/AD300 cells assessed as reversal of doxorubicin resistance by measuring doxorubicin IC50 at 2.5 uM after 48 hrs by MTT assay | B | 6.2 | pIC50 | 630 | nM | IC50 | J Med Chem (2022) 65: 2610-2622 [PMID:35067062] |
| ChEMBL | Inhibition of P-glycoprotein-mediated daunorubicin efflux from human CCRF-CEM/VCR1000 cells after 240 secs by FACS flow cytometric analysis | B | 6.24 | pIC50 | 575.44 | nM | IC50 | J Med Chem (2012) 55: 3261-3273 [PMID:22452412] |
| ChEMBL | Inhibition of human full-length ABCB1 expressed in FLp-In-293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 2264 +/- 196 nM) | B | 6.28 | pIC50 | 522 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of human MDR1 expressed in MDCK cells assessed as calcein AM accumulation after 30 mins by fluorescence assay | B | 6.3 | pIC50 | 500 | nM | IC50 | J Med Chem (2012) 55: 424-436 [PMID:22112208] |
| ChEMBL | Inhibition of human full-length ABCB1 expressed in FLp-In-293 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 823 +/- 16 nM) | B | 6.34 | pIC50 | 456 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of human full-length ABCB1 expressed in FLp-In-293 cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 797 +/- 73 nM) | B | 6.39 | pIC50 | 412 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC | F | 6.4 | pIC50 | 400 | nM | IC50 | J Med Chem (2003) 46: 1716-1725 [PMID:12699389] |
| ChEMBL | TP_TRANSPORTER: drug resistance (vincristine) in AML-2/D100 cells | F | 6.4 | pIC50 | 400 | nM | IC50 | Biochem Biophys Res Commun (2004) 320: 672-679 [PMID:15240100] |
| ChEMBL | Inhibition of ABCB1 in multidrug-resistant human SW620/Ad300 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 pre-incubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.6 uM) | B | 6.52 | pIC50 | 300 | nM | IC50 | J Med Chem (2020) 63: 15979-15996 [PMID:33280384] |
| ChEMBL | Inhibition of ABCB1 in human KB-VIN cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 2867 +/- 142 nM) | B | 6.71 | pIC50 | 195 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of ABCB1 in human HeLa S3 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 242 +/- 5 nM) | B | 7.07 | pIC50 | 85.7 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of ABCB1 in human KB-VIN cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 1762 +/- 63 nM) | B | 7.11 | pIC50 | 76.9 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 80 +/- 10 nM) | B | 7.12 | pIC50 | 76.4 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of P-glycoprotein in human LCC6MDR cells assessed as reversal fold by measuring reduction in paclitaxel by measuring paclitaxel IC50 at 1 uM after 5 days by Cell Titer-Glo luminescence assay | B | 7.42 | pIC50 | 38 | nM | IC50 | Eur J Med Chem (2021) 226: 113795-113795 [PMID:34597896] |
| ChEMBL | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay | B | 7.42 | pIC50 | 38 | nM | IC50 | J Med Chem (2015) 58: 4529-4549 [PMID:25985195] |
| ChEMBL | Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 5 uM measured after 72 hrs by MTT assay | B | 7.43 | pIC50 | 36.77 | nM | IC50 | Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797] |
| ChEMBL | Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 2.92 +/- 0.31 nM) | B | 7.46 | pIC50 | 35.02 | nM | IC50 | Eur J Med Chem (2019) 182: 111668-111668 [PMID:31505451] |
| ChEMBL | Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/- 0.004 uM) | B | 7.54 | pIC50 | 29 | nM | IC50 | Eur J Med Chem (2014) 87: 398-412 [PMID:25282263] |
| ChEMBL | Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 1353.98 +/- 303.33 nM) | B | 7.55 | pIC50 | 28.16 | nM | IC50 | Eur J Med Chem (2019) 161: 118-130 [PMID:30347326] |
| ChEMBL | Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM measured after 72 hrs by MTT assay | B | 7.64 | pIC50 | 23.08 | nM | IC50 | Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797] |
| ChEMBL | Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 352.31 +/- 10.9 nM) | B | 7.73 | pIC50 | 18.43 | nM | IC50 | Eur J Med Chem (2019) 182: 111668-111668 [PMID:31505451] |
| ChEMBL | Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 5 uM measured after 72 hrs by MTT assay | B | 7.78 | pIC50 | 16.49 | nM | IC50 | Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797] |
| ChEMBL | Inhibition of ABCB1 (unknown origin) expressed in HEK293 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 4 uM pre-incubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 91.40 +/- 23.32 nM) | B | 7.98 | pIC50 | 10.37 | nM | IC50 | J Med Chem (2020) 63: 15979-15996 [PMID:33280384] |
| ChEMBL | Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by MTT assay | B | 7.99 | pIC50 | 10.17 | nM | IC50 | Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797] |
| ChEMBL | Inhibition of ABCB1 in human HeLa S3 cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 26.50 +/- 4.1 nM) | B | 8.05 | pIC50 | 8.9 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 11.8 +/- 1.13 nM) | B | 8.07 | pIC50 | 8.6 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM measured after 72 hrs by MTT assay | B | 8.07 | pIC50 | 8.51 | nM | IC50 | Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797] |
| ChEMBL | Inhibition of ABCB1 in multidrug-resistant human KB-C2 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 4 uM pre-incubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM) | B | 8.15 | pIC50 | 7.05 | nM | IC50 | J Med Chem (2020) 63: 15979-15996 [PMID:33280384] |
| ChEMBL | Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 6 +/- 0.2 nM) | B | 8.17 | pIC50 | 6.7 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM measured after 72 hrs by MTT assay | B | 8.28 | pIC50 | 5.29 | nM | IC50 | Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797] |
| ChEMBL | Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM | B | 8.31 | pIC50 | 4.9 | nM | IC50 | Eur J Med Chem (2019) 161: 364-377 [PMID:30384042] |
| ChEMBL | Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by MTT assay | B | 8.34 | pIC50 | 4.59 | nM | IC50 | Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797] |
| ChEMBL | Inhibition of ABCB1 in human HeLa S3 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 2.5 uM measured after 72 hrs by SRB assay (Rvb = 4.55 +/- 0.28 nM) | B | 8.41 | pIC50 | 3.87 | nM | IC50 | Eur J Med Chem (2020) 201: 112422-112422 [PMID:32569926] |
| ChEMBL | Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM measured after 72 hrs by MTT assay | B | 8.53 | pIC50 | 2.97 | nM | IC50 | Eur J Med Chem (2021) 211: 113107-113107 [PMID:33360797] |
| ChEMBL | Inhibition of Pgp measured as inhibition of [3H]vinblastine basolateral to apical transport in Caco-2 cells | F | 4.7 | pEC50 | 20000 | nM | EC50 | J Med Chem (2006) 49: 6607-6613 [PMID:17064079] |
| ChEMBL | Inhibition of human P-glycoprotein mediated [3H]vinblastine transport in human Caco-2 cells | B | 4.7 | pEC50 | 20000 | nM | EC50 | J Med Chem (2008) 51: 1415-1422 [PMID:18257545] |
| ChEMBL | Inhibition of human Pgp mediated [3H]vinblastine transport in human Caco-2 cells | B | 4.7 | pEC50 | 20000 | nM | EC50 | Bioorg Med Chem (2008) 16: 362-373 [PMID:17936633] |
| ChEMBL | Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells | B | 4.7 | pEC50 | 20000 | nM | EC50 | Bioorg Med Chem Lett (2008) 18: 3741-3744 [PMID:18524592] |
| ChEMBL | Inhibition of P-glycoprotein (unknown origin) expressed in MDCK cells assessed as reduction of calcein-AM transport after 30 mins by fluorescence assay | B | 4.7 | pEC50 | 20000 | nM | EC50 | Eur J Med Chem (2014) 76: 558-566 [PMID:24607999] |
| ChEMBL | TP_TRANSPORTER: reversal of Vinblastine accumulation (Vinblastine: 0.005 uM) in MDA435/LCC6 MDR1 cells | F | 5.51 | pEC50 | 3100 | nM | EC50 | J Med Chem (2002) 45: 390-398 [PMID:11784143] |
| ChEMBL | Inhibition of p-gp in human KB/VCR cells assessed as potentiation of 100 nM docetaxel-induced cytotoxicity after 72 hrs by MTT assay | B | 5.9 | pEC50 | 1253 | nM | EC50 | Bioorg Med Chem (2013) 21: 4279-4287 [PMID:23683834] |
| ChEMBL | Reversal of P-gp-mediated multidrug resistance to vinblastine in human CEM/VLB500 cells after 3 days by resazurin assay | B | 5.98 | pEC50 | 1041 | nM | EC50 | Bioorg Med Chem (2007) 15: 3854-3868 [PMID:17399990] |
| ChEMBL | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing vinblastine resistance measured as cell survival after 5 days by MTS assay | B | 6.3 | pEC50 | 503 | nM | EC50 | J Med Chem (2015) 58: 4529-4549 [PMID:25985195] |
| ChEMBL | Inhibition of P-gp (unknown origin) expressed in MDCK-MDR1 cells assessed as increase in calcein-AM accumulation incubated for 30 mins by calcein-AM dye based fluorescence assay | B | 6.3 | pEC50 | 500 | nM | EC50 | Eur J Med Chem (2019) 182: 111655-111655 [PMID:31494468] |
| ChEMBL | Inhibition of P-glycoprotein (unknown origin) in MDCK-MDR1 assessed as inhibtion of calcein-AM transport incubated for 30 mins by fluorescence assay | B | 6.3 | pEC50 | 500 | nM | EC50 | Eur J Med Chem (2019) 172: 71-94 [PMID:30947123] |
| ChEMBL | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing paclitaxel resistance measured as cell survival after 5 days by MTS assay | B | 6.35 | pEC50 | 446 | nM | EC50 | J Med Chem (2015) 58: 4529-4549 [PMID:25985195] |
| ChEMBL | Modulation of P-gp in human MDA435/LCC6MDR cells assessed as reversal of paclitaxel resistance | B | 6.35 | pEC50 | 446 | nM | EC50 | Bioorg Med Chem (2015) 23: 5566-5573 [PMID:26233798] |
| ChEMBL | Modulation of p-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversal of paclitaxel resistance | B | 6.35 | pEC50 | 445.7 | nM | EC50 | J Med Chem (2013) 56: 9057-9070 [PMID:24171478] |
| ChEMBL | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing vincristine resistance measured as cell survival after 5 days by MTS assay | B | 6.41 | pEC50 | 385 | nM | EC50 | J Med Chem (2015) 58: 4529-4549 [PMID:25985195] |
| ChEMBL | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing doxorubicin resistance measured as cell survival after 5 days by MTS assay | B | 6.61 | pEC50 | 245 | nM | EC50 | J Med Chem (2015) 58: 4529-4549 [PMID:25985195] |
| ChEMBL | Compound was tested for inhibition of daunomycin efflux in the resistant human T-lymphoblast cell line CEM vcr1000. | F | 6.92 | pEC50 | 120 | nM | EC50 | J Med Chem (1998) 41: 4001-4011 [PMID:9767638] |
| P-glycoprotein 1 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3467] [UniProtKB: P06795] | ||||||||
| ChEMBL | Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay | F | 5.7 | pIC50 | 2000 | nM | IC50 | J Med Chem (2003) 46: 1716-1725 [PMID:12699389] |
| ChEMBL | TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells | F | 5.7 | pIC50 | 2000 | nM | IC50 | J Med Chem (2003) 46: 1716-1725 [PMID:12699389] |
| ABCB1/P-glycoprotein 3 in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2573] [GtoPdb: 768] [UniProtKB: P21447] | ||||||||
| ChEMBL | Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay | F | 5 | pIC50 | 10000 | nM | IC50 | J Med Chem (2003) 46: 1716-1725 [PMID:12699389] |
| ChEMBL | TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells | F | 5 | pIC50 | 10000 | nM | IC50 | J Med Chem (2003) 46: 1716-1725 [PMID:12699389] |
| Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
| ChEMBL | Inhibition of chloroquine-resistant Plasmodium falciparum D10 CRT expressed in Xenopus laevis oocytes assessed as [3H]-chloroquine uptake after 1 to 2 hrs | B | 4.52 | pIC50 | 30000 | nM | IC50 | Eur J Med Chem (2011) 46: 1729-1742 [PMID:21396749] |
| ChEMBL | In vitro inhibitory activity against multidrug-resistant Plasmodium falciparum W2 Indochina | F | 4.87 | pIC50 | 13400 | nM | IC50 | J Med Chem (2002) 45: 3195-3209 [PMID:12109904] |
| ChEMBL | Antimicrobial activity against Plasmodium falciparum | F | 4.89 | pIC50 | 13000 | nM | IC50 | Bioorg Med Chem (2010) 18: 2225-2231 [PMID:20185316] |
| ChEMBL | Antimalarial activity after 72 hrs against chloroquine-resistant transporter 106/1'76I mutant Plasmodium falciparum infected in human erythrocytes by SYBR green assay | F | 5.15 | pIC50 | 7074 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 4133-4140 [PMID:17846138] |
| ChEMBL | Antimalarial activity after 72 hrs against chloroquine-resistant transporter 106/1'76T mutant Plasmodium falciparum infected human erythrocytes by SYBR green assay | F | 5.39 | pIC50 | 4053 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 4133-4140 [PMID:17846138] |
| ChEMBL | Antimalarial activity after 72 hrs against chloroquine-resistant Plasmodium falciparum Dd2 infected human erythrocytes by SYBR green assay | F | 5.7 | pIC50 | 2000 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 4133-4140 [PMID:17846138] |
| ChEMBL | Antimalarial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes by SYBR green assay | F | 5.89 | pIC50 | 1300 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 4133-4140 [PMID:17846138] |
| ChEMBL | Concentration required to reduce chloroquine IC50 by 50% | F | 6.1 | pIC50 | 800 | nM | IC50 | J Med Chem (2002) 45: 3195-3209 [PMID:12109904] |
| ChEMBL | Antimalarial activity after 72 hrs against chloroquine-resistant transporter 106/1'76N mutant Plasmodium falciparum infected human erythrocytes by SYBR green assay | F | 6.19 | pIC50 | 653 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 4133-4140 [PMID:17846138] |
| 5-HT1A receptor/Serotonin 1a (5-HT1a) receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL273] [GtoPdb: 1] [UniProtKB: P19327] | ||||||||
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) | B | 5.76 | pKi | 1726 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) | B | 5.52 | pIC50 | 3020 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| 5-HT2A receptor/Serotonin 2a (5-HT2a) receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL224] [GtoPdb: 6] [UniProtKB: P28223] | ||||||||
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) | B | 6.9 | pKi | 126 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) | B | 6.35 | pIC50 | 442 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| 5-HT2B receptor/Serotonin 2b (5-HT2b) receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1833] [GtoPdb: 7] [UniProtKB: P41595] | ||||||||
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | B | 6.98 | pKi | 105 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | B | 6.78 | pIC50 | 165 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| 5-HT2C receptor/Serotonin 2c (5-HT2c) receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL225] [GtoPdb: 8] [UniProtKB: P28335] | ||||||||
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) | B | 6.81 | pKi | 155 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) | B | 6.53 | pIC50 | 297 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| SERT/Serotonin transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL228] [GtoPdb: 928] [UniProtKB: P31645] | ||||||||
| ChEMBL | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | B | 6.9 | pKi | 127 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) | B | 6.62 | pIC50 | 240 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| Nav1.5/Sodium channel protein type V alpha subunit in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1980] [GtoPdb: 582] [UniProtKB: Q14524] | ||||||||
| ChEMBL | Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA | F | 4.38 | pIC50 | 41500 | nM | IC50 | Cardiovasc Res (2011) 91: 53-61 [PMID:21300721] |
| Organic cation transporter 1/Solute carrier family 22 member 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5685] [GtoPdb: 1019] [UniProtKB: O15245] | ||||||||
| ChEMBL | TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells | F | 5.54 | pKi | 2900 | nM | Ki | J Pharmacol Exp Ther (1998) 286: 354-361 [PMID:9655880] |
| ChEMBL | Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy | B | 5.17 | pIC50 | 6800 | nM | IC50 | J Med Chem (2008) 51: 5932-5942 [PMID:18788725] |
| Voltage-dependent L-type calcium channel subunit alpha-1C in Guinea pig (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2366456] [UniProtKB: O35505] | ||||||||
| ChEMBL | Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in guinea pig ventricular myocytes | F | 5.74 | pIC50 | 1800 | nM | IC50 | IC50 data for the L-type calcium channel extracted from a set of literature articles |
| ChEMBL | Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in guinea pig ventricular myocytes | F | 5.82 | pIC50 | 1500 | nM | IC50 | IC50 data for the L-type calcium channel extracted from a set of literature articles |
| ChEMBL | Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes | F | 6.03 | pIC50 | 940 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| ChEMBL | Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes | F | 6.1 | pIC50 | 790 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| ChEMBL | Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes | F | 6.22 | pIC50 | 600 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| ChEMBL | Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes | F | 6.79 | pIC50 | 164 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| ChEMBL | Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes | F | 7 | pIC50 | 100 | nM | IC50 | Cardiovasc Res (2011) 91: 53-61 [PMID:21300721] |
| ChEMBL | Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes | F | 7 | pIC50 | 100 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| Cav1.2/Voltage-gated L-type calcium channel alpha-1C subunit in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1940] [GtoPdb: 529] [UniProtKB: Q13936] | ||||||||
| ChEMBL | Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit | F | 4.3 | pIC50 | 50000 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| ChEMBL | Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit | F | 4.33 | pIC50 | 47000 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| ChEMBL | Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit | F | 4.62 | pIC50 | 24000 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| ChEMBL | Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Chinese hamster ovary cells heterologically expressing alpha-1C subunit | F | 4.63 | pIC50 | 23500 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| ChEMBL | Inhibition of (-)-[3H]- D-888 binding to L-type calcium channels in kitten heart ventricle membranes | B | 6.82 | pIC50 | 150 | nM | IC50 | J Med Chem (1993) 36: 439-445 [PMID:8474099] |
| Voltage-gated L-type calcium channel alpha-1C subunit in Rabbit (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2830] [UniProtKB: P15381] | ||||||||
| ChEMBL | Inhibition of [3H]nitrendipine binding to calcium channels in Rabbit cardiac muscle. | B | 6 | pIC50 | 1000 | nM | IC50 | J Med Chem (1988) 31: 2221-2227 [PMID:3184128] |
| Cav1.2/Voltage-gated L-type calcium channel alpha-1C subunit in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3762] [GtoPdb: 529] [UniProtKB: P22002] | ||||||||
| GtoPdb | - | - | 6.5 | pIC50 | - | - | - | Mol Pharmacol (1996) 50: 1388-400 [PMID:8913371] |
| GtoPdb | - | - | 6.5 | pIC50 | - | - | - | Mol Pharmacol (1996) 50: 1388-400 [PMID:8913371] |
| ChEMBL | Ability to inhibit [3H]nitrendipine binding to the L-type calcium channel receptor(CCR) in rat heart homogenate. | B | 7.41 | pIC50 | 39 | nM | IC50 | J Med Chem (1996) 39: 2922-2938 [PMID:8709127] |
| Cav1.1 in Rabbit [GtoPdb: 528] | ||||||||
| GtoPdb | - | - | 5 | pIC50 | ~10000 | nM | IC50 | J Pharmacol Exp Ther (1986) 236: 403-7 [PMID:2418195] |
| Cav1.1/Voltage-gated L-type calcium channel alpha-1S subunit in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4108] [GtoPdb: 528] [UniProtKB: Q02485] | ||||||||
| ChEMBL | Inhibition of [3H]D-888 binding to L-type [Ca2+] channel of membranes from rat skeletal muscle | B | 7.24 | pKi | 58 | nM | Ki | J Med Chem (1996) 39: 4099-4108 [PMID:8831775] |
| Kv1.3/Voltage-gated potassium channel subunit Kv1.3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4633] [GtoPdb: 540] [UniProtKB: P22001] | ||||||||
| ChEMBL | Inhibition of Kv1.3 expressed in mouse L929 cells exposed to depolarizing step pulses from -80 mV to +40 mV by whole cell patch clamp method | B | 5.1 | pIC50 | 8000 | nM | IC50 | Bioorg Med Chem Lett (2012) 22: 7106-7109 [PMID:23084278] |
| TPC1 in Human [GtoPdb: 392] [UniProtKB: Q9ULQ1] | ||||||||
| GtoPdb | - | - | 4.64 | pIC50 | 23000 | nM | IC50 | Nat Chem Biol (2014) 10: 463-9 [PMID:24776928] |
| TPC2 in Human [GtoPdb: 393] [UniProtKB: Q8NHX9] | ||||||||
| GtoPdb | - | - | 5 | pIC50 | 10000 | nM | IC50 | Cell (2012) 151: 372-83 [PMID:23063126] |
| Kir3.2 in Mouse [GtoPdb: 435] [UniProtKB: P48542] | ||||||||
| GtoPdb | - | - | 3.9 | pIC50 | - | - | - | Neuron (1996) 16: 941-52 [PMID:8630252] |
| Cav1.3 in Mouse [GtoPdb: 530] [UniProtKB: Q99246] | ||||||||
| GtoPdb | - | - | 3.7 | pIC50 | - | - | - | Eur J Pharmacol (2007) 573: 39-48 [PMID:17651721] |
| Kv1.7 in Human [GtoPdb: 544] [UniProtKB: Q96RP8] | ||||||||
| GtoPdb | - | - | 4.8 | pKd | - | - | - | Eur J Hum Genet (2002) 10: 36-43 [PMID:11896454] |
| Kv1.8 in Human [GtoPdb: 545] [UniProtKB: Q16322] | ||||||||
| GtoPdb | - | - | 4.3 | pIC50 | - | - | - | Am J Physiol Renal Physiol (2000) 278: F1013-21 [PMID:10836990] |
| Kv3.2 in Rat [GtoPdb: 549] [UniProtKB: P22462] | ||||||||
| GtoPdb | - | - | 4.9 | pEC50 | - | - | - | Neuropharmacology (2000) 39: 202-10 [PMID:10670415] |
| Navi2.1 in Human [GtoPdb: 750] [UniProtKB: Q8IZF0] | ||||||||
| GtoPdb | - | - | 3.4 | pIC50 | 380000 | nM | IC50 | |
| Plasma membrane monoamine transporter in Human [GtoPdb: 1120] [UniProtKB: Q7RTT9] | ||||||||
| GtoPdb | - | - | 4.73 | pKi | 18600 | nM | Ki |
Mol Pharmacol (2005) 68: 1397-407 [PMID:16099839]; Clin Pharmacol Ther (2016) 100: 489-499 [PMID:27506881] |
| CYP3A4 in Human [GtoPdb: 1337] [UniProtKB: P08684] | ||||||||
| GtoPdb | Inhibition of testosterone 6β-hydroxylation. | - | 6.22 | pKi | 600 | nM | Ki | Br J Clin Pharmacol (2001) 51: 461-70 [PMID:11422004] |
ChEMBL data shown on this page come from version 33:
Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
